Rasonque

News

The RAS inhibitor for pancreatic cancer that received a standing ovation at ASCO for its doubling of overall survival now has its FDA approval.

News

Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.